Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 4Dermatologic 3Tumor-Agnostic 1Other hematologic neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 2Lymphoma, T-Cell, Cutaneous 1Lymphoma 1

Interventions

pembrolizumab 81Nivolumab 55Ipilimumab 44Cyclophosphamide 38aldesleukin 26Interleukin-2 25fludarabine 17Temozolomide 17fludarabine phosphate 16trametinib 11dabrafenib 11Radiotherapy 11Biopsy 11avelumab 10Paclitaxel 9spartalizumab 8cemiplimab 8Dacarbazine 8Cisplatin 8Bevacizumab 8sargramostim 7binimetinib 7Fluorouracil 7poly ICLC 6lenvatinib 6epacadostat 6atezolizumab 6Magnetic Resonance Spectroscopy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × ProMune × Dermatologic × Clear all
NCT00145158 2022-10-10

Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma

Ludwig Institute for Cancer Research

Phase 1/2 Terminated
23 enrolled 8 charts
Dermatologic

Melanoma

NCT00145145 2022-10-07

Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma

Ludwig Institute for Cancer Research

Phase 1/2 Terminated
1 enrolled 4 charts
Dermatologic

Melanoma

NCT00043420 2009-02-12

CPG 7909 in Patients With Cutaneous T-Cell Lymphoma

Pfizer

Phase 1/2 Completed
42 enrolled
DermatologicLymphoid

Lymphoma, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡